• CD103+ Tregs express higher levels of TNFR2 than CD103- Tregs in the spleen and tumor (CT26 and BNL cell model)• Blockade by an anti-TNFR2 mAb or by a soluble TNFR2 fusion protein (sTNFR2-Fc) inhibits TNF-α-induced expansion of CD103+ Tregs in vitro• Blockade by sTNFR2-Fc after cyclophosphamide treatment• inhibits tumor growth. This evidence concerns the gene TNFRSF1B and neoplasm.